Latest Biotech News

Researchers argue that Europe’s clinical development bottlenecks are not solved by faster regulatory approvals alone. In a study published in Clinical Microbiology and Infection, authors point to...

Eli Lilly agreed to license Hanmi Pharmaceutical’s long-acting GLP-2 analog sonefpeglutide in a $1.26 billion transaction structured around an upfront payment and milestone-based consideration....

Servier agreed to acquire Edgewise Therapeutics’ muscular dystrophy program for $1.55 billion upfront, with total deal value potentially rising to $2.65 billion including milestones. The...

Eli Lilly’s acquisition of Kelonia Therapeutics is providing a rapid payoff: Kelonia delivered an in vivo CAR-T update at ASCO 2026 showing complete responses across the multiple myeloma cohort...

RallyBio pivoted again to re-enter public markets via a reverse merger with Avenzo Therapeutics after earlier merger plans collapsed following UCB’s acquisition of Candid Therapeutics. The...

A research team led by Luigi Naldini at the San Raffaele Telethon Institute for Gene Therapy (SR-Tiget) reported a new gene-editing strategy—called SMArT—that aims to improve precision and safety...

The FDA roadmap to reduce reliance on animal testing is accelerating interest in organ-on-chip systems, the article reports. In April 2025, the FDA signaled that animal testing should become the...

A low-cost workflow reported by researchers enables fabrication of 100,000 uniform cell capsules using standard laboratory tools. By encapsulating cells in hydrogel microcapsules, the method...

Ropsacitinib (PF-06826647) has moved into Phase 2 testing for plaque psoriasis and hidradenitis suppurativa, extending the competitive field of TYK2 kinase inhibition. The program positions the...

FDA approval cleared Foundation Medicine CDx assays as companion diagnostics for Pfizer’s Talzenna plus Xtandi regimen in metastatic castration-resistant prostate cancer. The decision authorizes...

Eli Lilly expanded its GLP-2 strategy through a licensing deal with Hanmi Pharm for sonefpeglutide, a long-acting GLP-2 analog being developed in short bowel syndrome (SBS). Lilly will pay $75...

A research team led by Luigi Naldini at the San Raffaele Telethon Institute for Gene Therapy (SR-Tiget) unveiled an improved CRISPR-Cas9 strategy aimed at increasing precision and safety in human...

Servier agreed to acquire Edgewise Therapeutics’ muscular dystrophy assets in a transaction worth up to $2.65 billion, centered on sevasemten. The deal includes a $1.55 billion upfront payment...

Researchers presented an AI-driven spatial biomarker, ST-DoxPCa, designed to predict which patients with metastatic hormone-sensitive prostate cancer may benefit from adding docetaxel to androgen...

Pfizer and Innovent Biologics announced a back-heavy cancer collaboration involving 12 antibody-based therapies, combining Pfizer’s funding and Innovent’s contributed assets across oncology...

Agios signed an exclusive global licensing deal for Oscotec’s cevidoplenib, a next-generation SYK inhibitor being developed for immune thrombocytopenia (ITP), despite Oscotec’s Phase 2 failure to...

Replimune said it will resubmit its biologics license application for RP1 for advanced melanoma as an urgent matter, aiming to return the therapy to the FDA review queue for a third time. The move...

Revolution Medicines presented expanded Phase 3 results for daraxonrasib at ASCO, showing markedly longer survival versus standard chemotherapy in metastatic pancreatic cancer driven by KRAS G12...

Servier agreed to acquire Edgewise Therapeutics’ muscular dystrophy business for $1.55 billion upfront, with total consideration up to $2.65 billion including potential milestones. The deal gives...

Revolution Medicines reported expanded ASCO data for daraxonrasib in second-line metastatic pancreatic cancer, highlighting a survival benefit in patients with KRAS/ RAS G12 mutations and in the...